Drug Patents owned by Nalpropion

1. Drug name - CONTRAVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7462626 NALPROPION Compositions for affecting weight loss Jul, 2024

(1 year, 9 months from now)

US8815889 NALPROPION Compositions and methods for increasing insulin sensitivity Jul, 2024

(1 year, 9 months from now)

US7375111 NALPROPION Compositions for affecting weight loss Mar, 2025

(2 years from now)

US9107837 NALPROPION Sustained release formulation of naltrexone Jun, 2027

(4 years from now)

US8722085 NALPROPION Methods for administering weight loss medications Nov, 2027

(5 years from now)

US9125868 NALPROPION Methods for administering weight loss medications Nov, 2027

(5 years from now)

US10307376 NALPROPION Methods for administering weight loss medications Nov, 2027

(5 years from now)

US8318788 NALPROPION Layered pharmaceutical formulations Nov, 2027

(5 years from now)

US8088786 NALPROPION Layered pharmaceutical formulations Feb, 2029

(6 years from now)

US8916195 NALPROPION Sustained release formulation of naltrexone Feb, 2030

(7 years from now)

US11033543 NALPROPION Methods of providing weight loss therapy in patients with major depression Jan, 2031

(8 years from now)

US9248123 NALPROPION Methods of providing weight loss therapy in patients with major depression Jan, 2032

(9 years from now)

US10403170 NALPROPION Methods of treating overweight and obesity Jun, 2033

(10 years from now)

US11139056 NALPROPION Methods of treating overweight and obesity Jun, 2033

(10 years from now)

US9633575 NALPROPION Methods of treating overweight and obesity Jun, 2033

(10 years from now)

US10828294 NALPROPION Compositions and methods for weight loss in at risk patient populations Jul, 2034

(11 years from now)

US10835527 NALPROPION Compositions and methods for reducing major adverse cardiovascular events Jul, 2034

(11 years from now)

US10231964 NALPROPION Compositions and methods for weight loss in at risk patient populations Jul, 2034

(11 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance; Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity; Use of naltrexone and bupropion based on an escalating dose schedule; Use of naltrexone and bupropion in a layered formulation for chronic weight management for affecting weight loss; Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
90MG;8MG TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.